Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference
September 08 2020 - 7:00AM
Business Wire
Sesen Bio (Nasdaq: SESN), a late-stage clinical company
developing targeted fusion protein therapeutics for the treatment
of patients with cancer, today announced it will be featured as a
presenting company at the H. C. Wainwright 22nd Annual Global
Investment Conference on Tuesday, September 15, 2020.
Event: H. C. Wainwright 22nd Annual Global Investment Conference
Date: September 15, 2020 Time: 10:30 - 10:50 AM ET
A live webcast of the Company’s presentation will be accessible
from the Investors & Media section of the Sesen Bio website,
www.sesenbio.com. An archived replay of the webcast will be
available on the Company's website for 90 days after the
conference.
About Sesen Bio Sesen Bio, Inc. is a late-stage clinical
company advancing targeted fusion protein therapeutics for the
treatment of patients with cancer. The Company’s lead program,
Vicineum™, also known as VB4-845, is currently in the follow-up
stage of a Phase 3 registration trial for the treatment of
high-risk, BCG-unresponsive non-muscle invasive bladder cancer
(NMIBC). In December 2019, the Company initiated the BLA submission
for Vicineum to the FDA under Rolling Review. Sesen Bio retains
worldwide rights to Vicineum with the exception of Greater China,
for which the Company has partnered with Qilu Pharmaceutical for
commercialization. Vicineum is a locally administered targeted
fusion protein composed of an anti-EpCAM antibody fragment tethered
to a truncated form of Pseudomonas Exotoxin A for the treatment of
high-risk NMIBC. For more information, please visit the company’s
website at www.sesenbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200908005078/en/
Erin Clark, Vice President, Corporate Strategy & Investor
Relations ir@sesenbio.com
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Sep 2023 to Sep 2024